Serum IL-8 has been shown to be higher in patients with pancreatic cancer than controls; however, the mean AUC value for IL-8 alone is poor and improved when included in a panel with other biomarkers (77–79). This evidence concerns the gene CXCL8 and pancreatic neoplasm.